FDA's 17 Revised Peptide Guidances: What Generic Developers Must Change

On 28 July 2026, the United States Food and Drug Administration (FDA) published 17 revised draft product-specific guidances (PSGs) for peptide products and, on the same day, withdrew the framework that many synthetic-peptide programmes were built on. For generic developers working on semaglutide, tirzepatide, liraglutide and other high-value peptides, this is the most significant shift in the abbreviated new drug application (ANDA) pathway for peptides in years.

The revised guidances were carried in the Federal Register on 29 July 2026, and the public comment window closes on 28 September 2026. If your programme is mid-development, the practical message is simple: the expectations you designed your chemistry, manufacturing and controls (CMC) package around have moved, and you have a narrow window to respond. This article explains what changed, why it matters, and the concrete steps sponsors should take now.

Executive Summary

Here is the short version for busy regulatory and quality leaders.

• What happened: FDA published 17 revised draft PSGs for peptide products on 28 July 2026 and withdrew its May 2021 synthetic-peptide guidance the same day.
• Scope: The revised PSGs cover calcitonin salmon, dasiglucagon, glucagon, liraglutide, pegcetacoplan, semaglutide, teriparatide, tirzepatide and vosoritide reference products.
• Five technical areas changed: submission of recombinant, synthetic and semi-synthetic peptides as ANDAs, innate immune response testing, impurity thresholds, higher order structure assessment, and biological activity assessment.
• The withdrawn baseline: The 2021 guidance no longer reflects FDA's current scientific thinking. Per the CDER 2026 Guidance Agenda, FDA plans to revise the guidance this year, but no replacement text or firm date has been published.
• The deadline: Comments on the revised draft PSGs close 28 September 2026.
• What to do: Re-baseline your CMC and analytical package against the revised PSGs, prioritise impurity and higher-order-structure work, and decide whether to file a comment.

What FDA Changed, and What a PSG Actually Is

What is it? A product-specific guidance is FDA's published recommendation on how to demonstrate that a proposed generic product is therapeutically equivalent to a specific reference listed drug. It tells an ANDA sponsor which studies, tests and comparative data the Office of Generic Drugs (OGD) expects. Why does it matter? For complex molecules like peptides, the PSG is effectively the blueprint for the whole development programme. What should companies do? Read the revised PSG for your target product line by line and map every recommendation against your current plan.

On 28 July 2026 FDA revised the PSGs for the peptide reference products listed below. Each guidance is tied to a specific reference listed drug and its new drug application (NDA) number.

The Five Technical Areas That Changed

What is it? FDA's updated recommendations concentrate on five scientific areas. Why does it matter? These are exactly the areas where synthetic and semi-synthetic peptides differ most from small molecules, and where an ANDA is most likely to receive a deficiency. How does it affect compliance? Each area maps to specific CMC documents and analytical methods that may now need revision or revalidation.

For most programmes, the impurity threshold and higher-order-structure expectations are the highest-risk changes. Impurity work drives your analytical method development, your reference standard strategy and your specification setting. Higher-order-structure characterisation often requires orthogonal analytical techniques that a small-molecule generic team may not have in place. If your analytical package was built to an older recommendation, both areas are likely to need attention.

The Withdrawn 2021 Guidance: What It Means

What is it? On the same day, FDA withdrew the guidance for industry titled ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (May 2021). Why does it matter? Many synthetic-peptide programmes, especially those referencing peptides originally made by recombinant DNA methods, were designed around that document. What should companies do? Identify every place your development rationale cites or relies on the 2021 guidance and reassess it against the revised PSGs.

FDA stated that the 2021 guidance no longer reflects the agency's current scientific thinking. Importantly, the agency did not leave a vacuum by accident: the Center for Drug Evaluation and Research (CDER) 2026 Guidance Agenda indicates FDA plans to revise the guidance this year. Until that revised text appears, sponsors are working from the product-specific guidances plus general ANDA principles, without a dedicated horizontal guidance on synthetic peptides referencing rDNA-origin drugs.

Why This Matters for Your Compliance and Your Timeline

The revised PSGs are draft, but drafts describe FDA's current thinking and shape how the Office of Generic Drugs assesses applications in practice. Three consequences follow for sponsors.

First, your CMC baseline may have shifted. If impurity thresholds or higher-order-structure expectations changed for your target, your specifications, methods and stability commitments may no longer align. Filing against an outdated understanding invites deficiency letters and lost review cycles.

Second, analytical capability is now a gating factor. Higher-order-structure and biological-activity expectations demand orthogonal, validated methods. Building or transferring these methods takes time, and analytical method validation cannot be compressed at the end of a programme without risk.

Third, the comment window is a strategic asset. Because the guidances are draft, sponsors and industry groups can submit comments before 28 September 2026. A well-argued comment on an impractical or ambiguous recommendation can shape the final text and reduce future cost for the whole sector.

What Sponsors Should Do Now: A Step-by-Step Response

A disciplined response protects your timeline and your data integrity. We recommend the following sequence for any active or near-term peptide ANDA programme.

• Step 1: Pull the specific PSG for your product. Read the revised draft in full and extract every recommendation into a traceable requirements list.
• Step 2: Run a gap assessment. Compare each recommendation against your current CMC and analytical package. Flag gaps in impurity control, higher-order-structure characterisation and biological-activity testing first.
• Step 3: Re-baseline your impurity strategy. Confirm your identification and qualification thresholds, your reference standards and your handling of sequence variants and aggregates against the revised expectations.
• Step 4: Check your analytical methods. Identify methods that need development, transfer or revalidation, and build the timeline before it becomes the critical path.
• Step 5: Decide on a comment. If a recommendation is ambiguous, disproportionate or technically impractical, prepare a docket comment before 28 September 2026, supported by data where possible.
• Step 6: Consider controlled correspondence or a meeting. For unresolved questions, FDA encourages sponsors to engage the Office of Generic Drugs through a formal meeting request or controlled correspondence rather than guessing.

Peptide ANDA Compliance Checklist

Use this checklist to structure your internal review. Every item should have a named owner and a target date.

• The revised PSG for each target product has been retrieved and read in full.
• Every PSG recommendation is captured in a traceable requirements matrix.
• A documented gap assessment compares each recommendation against the current CMC package.
• Impurity identification and qualification thresholds are confirmed against the revised guidance.
• Sequence variants, aggregates and process-related impurities have defined control strategies.
• Higher-order-structure characterisation uses appropriate orthogonal analytical methods.
• Biological or functional activity is demonstrated with a suitable, validated assay.
• Innate immune response risk from impurities has been assessed.
• Analytical methods requiring development, transfer or revalidation are on a resourced timeline.
• A decision has been made on whether to submit a docket comment before 28 September 2026.
• Any reliance on the withdrawn 2021 guidance has been identified and reassessed.

Common Mistakes Generic Developers Make

From our regulatory and quality work with sponsors and contract manufacturers, these are the errors that most often cost review cycles.

• Treating a draft guidance as optional. Draft PSGs reflect FDA's current thinking and drive real assessment outcomes. Waiting for a final version is not a strategy.
• Leaving analytical method validation to the end. Higher-order-structure and activity methods take months to develop and validate. Late starts become the critical path and force rushed, error-prone work.
• Underqualifying impurities. Peptide-related impurities, sequence variants and aggregates are frequent deficiency topics. Thin qualification packages invite questions.
• Ignoring the comment window. Sponsors complain privately about impractical recommendations but never file a comment, forfeiting the one formal chance to shape the final text.
• Assuming the withdrawal loosened requirements. The 2021 withdrawal removed a framework, not a standard. Rebuild the justification, do not delete it.
• Relying on a certificate of analysis instead of independent testing. For complex peptides, FDA expects the applicant to establish identity and quality directly, not simply to accept a supplier's paperwork.

Real-World Lessons from Peptide and Complex-Molecule Programmes

Regulatory theory is one thing; assessment outcomes are another. The patterns below come from recurring findings in generic and complex-molecule programmes and show where the revised expectations bite in practice.

Impurity control is where most cycles are lost. In our experience reviewing CMC packages, the most common deficiency theme is incomplete qualification of peptide-related impurities and aggregates. Sponsors who set specifications without a defensible qualification rationale receive information requests that add months. The same discipline that supports a strong supplier qualification programme applies to your starting-material and reference-standard controls: know your inputs, tier the risk, and document the evidence.

Stability and specification setting must move together. Higher-order-structure and impurity expectations interact directly with your stability programme, because degradation pathways generate exactly the impurities FDA now scrutinises. If you are already revisiting stability under the wider 2026 changes, align that work with your peptide programme; our overview of the ICH Q1 stability overhaul explains how the stability landscape shifted this year.

Data integrity is assessed alongside the science. An ANDA package is only as strong as the records behind it. Analytical data for impurities and structure must be complete, attributable and reviewed, because incomplete audit trails and untraceable results are among the most cited problems in FDA enforcement. Our analysis of why data integrity still drives most FDA warning letters and of audit trail review as the new data integrity battleground shows why this cannot be an afterthought.

Enforcement is the cost of getting it wrong. If a deficiency escalates to an inspection observation, the response window is tight and the stakes are high. Sponsors who understand how to respond to an FDA Form 483 or a Health Canada inspection observation recover faster and protect their filing. And for teams also navigating the Canadian side of peptide regulation, our guide on whether peptides such as BPC-157 are legal in Canada sets out how Health Canada classifies these molecules.

Frequently Asked Questions

What is a product-specific guidance (PSG)?

A product-specific guidance is FDA's published recommendation on how to establish that a proposed generic product is therapeutically equivalent to a named reference listed drug. For peptides, it sets out the analytical, impurity and comparability data the Office of Generic Drugs expects in an ANDA.

Which peptides are covered by the 2026 revised guidances?

The 17 revised PSGs cover reference products for calcitonin salmon, dasiglucagon, glucagon, liraglutide, pegcetacoplan, semaglutide, teriparatide, tirzepatide and vosoritide, spanning diabetes, obesity, osteoporosis, macular degeneration and related indications.

When is the deadline to comment on the revised guidances?

The public comment period closes on 28 September 2026. Because the guidances are draft, comments submitted to the docket are considered by FDA before the PSGs are finalised.

Did FDA make peptide ANDAs easier or harder?

Neither framing is accurate. FDA updated its scientific expectations across five areas and withdrew an older framework. Some sponsors will find their existing plans well aligned, while others, especially those relying on the withdrawn 2021 guidance, will need to do additional impurity and structural work.

What happened to the 2021 synthetic-peptide guidance?

FDA withdrew the May 2021 guidance on ANDAs for certain highly purified synthetic peptide drug products referring to listed drugs of rDNA origin, stating it no longer reflects current scientific thinking. Per the CDER 2026 Guidance Agenda, FDA plans to revise the guidance this year, but no replacement has yet been published.

Do the revised guidances apply to peptides not on the list?

FDA noted that the recommendations may also apply to the development of other generic peptide products. For peptides without a dedicated PSG, sponsors are encouraged to contact the Office of Generic Drugs through a formal meeting request or controlled correspondence.

How does this affect Canadian or EU peptide programmes?

These guidances are FDA documents for the United States market. However, the underlying science on impurities, higher-order structure and comparability increasingly aligns across regulators. Sponsors pursuing multiple markets should ensure their analytical and impurity strategies satisfy the most demanding expectation across their target jurisdictions.

How MFLRC Can Help

MF License and Regulatory Consultants (MFLRC) provides senior-led regulatory and quality support for complex-molecule programmes across Canada, the United States and Europe. For peptide developers responding to the revised FDA guidances, our team can:

• Run a CMC and analytical gap assessment against the revised PSG for your specific product.
• Build an impurity qualification and control strategy, including sequence variants and aggregates.
• Design an analytical method validation plan for higher-order-structure and biological-activity testing.
• Draft a docket comment on your behalf, supported by technical rationale, before the 28 September 2026 deadline.
• Strengthen your data integrity and documentation so your ANDA package withstands assessment.
• Support regulatory strategy and agency engagement, including controlled correspondence and meeting preparation.

Our consultants combine deep quality-systems experience with practical regulatory affairs, so you receive defensible, inspection-ready deliverables rather than generic checklists. Explore our quality control and analytical support services and our regulatory affairs, licensing and import/export services to see how we work.

Conclusion

FDA's 17 revised peptide guidances, paired with the withdrawal of the 2021 synthetic-peptide guidance, reset the CMC baseline for generic peptide development. The changes concentrate on impurities, higher-order structure and biological activity, exactly the areas where peptides are hardest to characterise and where deficiencies most often arise. Sponsors who re-baseline early, resource their analytical work properly and use the comment window will protect their timelines. Those who wait for the final text risk building an ANDA on expectations that have already moved. The deadline of 28 September 2026 is close, and the work of gap assessment and method planning is best started now.

Sources and References

• FDA, FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products (28 July 2026).
• Federal Register, Product-Specific Guidances; Revised Draft Guidances for Industry; Availability (29 July 2026).
• FDA, Product-Specific Guidances for Generic Drug Development database.
• FDA, Drug Competition Action Plan.